Edwards Lifesciences

Current directors and officers who also hold a role at another S&P 500 company.

• David T. FeinbergHUM · Director
• Scott B. UllemILMN · Director
• Theodora MistrasVTRS · CFO

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Aug 28, 2026

   The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027. 2

   Read the 8-K filing
2. May 8, 2026

   Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”). The amendment approved by stockholders included an increase in the total number of shares of Edwards common stock available for issuance under the Long-Term Stock Program by 7,000,000 shares to a new total share limit of 341,500,000 shares. The complete terms of the Long-Term Stock Program amendment is qualified in its entirety by reference to the full text of the Amended and Restated Long-Term Stock Program, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

   Read the 8-K filing
3. May 4, 2026

   On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position. Ms. Mistras, age 44, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024. Prior to joining Viatris, Inc. as CFO-elect in January 2024, Ms. Mistras was Managing Director, Healthcare Investment Banking at Citigroup Global Markets from September 2019 to December 2023 and prior to that was Managing Director, Healthcare Investment Banking at Goldman Sachs, where she spent over 15 years in their investment banking healthcare group. In connection with her appointment as Corporate Vice President, Chief Financial Officer, Ms.

   Read the 8-K filing
4. Oct 30, 2025

   On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026. On October 30, 2025, the Corporation issued a press release announcing his decision. The Corporation is initiating a selection process to appoint a new Chief Financial Officer.

   Read the 8-K filing
5. Jul 25, 2025

   Departure of Named Executive Officer On July 21, 2025, Larry L. Wood notified the Board of Directors of Edwards Lifesciences Corporation (the “Company”) that he will resign from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart of the Company, effective September 1, 2025, to accept a senior leadership position at another company outside cardiovascular. In connection with Mr. Wood’s departure, effective September 1, 2025, Daniel J. Lippis, the Company’s current Corporate Vice President, Japan, Greater China and Asia Pacific, will serve as the Company’s Corporate Vice President responsible for Transcatheter Aortic Valve Replacement.

   Read the 8-K filing
6. May 8, 2025

   Approval of the Amendment and Restatement of the U.S. ESPP and the International ESPP At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved (i) the amendment and restatement of the Company’s 2001 Employee Stock Purchase Plan for United States Employees (the “U.S. ESPP”) to increase the total number of shares of common stock available for issuance under the U.S. ESPP by 4,200,000 shares, and (ii) the amendment and restatement of the Company’s 2001 Employee Stock Purchase Plan for International Employees (the “International ESPP”) to increase the total number of shares of common stock available for issuance under the International ESPP by 1,460,000 shares. The complete terms of the U.S.

   Read the 8-K filing
7. Jul 10, 2024

   On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately. The Board also appointed Dr. Feinberg to serve as a member of the Audit Committee of the Board. David T. Feinberg, M.D., age 62, has been serving as the Chairman of Oracle Health since 2022, when Oracle Corporation acquired Cerner Corporation, where he served as CEO from 2021 to 2022. Dr. Feinberg brings almost three decades of experience in health system and health information technology services management, including serving as Vice President at Google Health from 2019 to 2021, where he led Google’s health efforts. Prior to that, Dr. Feinberg was President and CEO at Geisinger Health, a physician-led health system. And from 2008 to 2015, Dr.

   Read the 8-K filing
8. Jun 17, 2024

   Principal Accounting Officer Retirement and Succession The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024 (the “Retirement Date”). On the Retirement Date, Mr. Sellers will be succeeded by Andrew M. Dahl, currently Senior Vice President and Corporate Controller of the Company. Mr. Dahl, age 47, joined Edwards in February 2024 as Corporate Controller. Prior to joining Edwards, Mr. Dahl served in positions of increasing responsibility at Medtronic PLC, a medical device company, since May 2016, serving most recently as Vice President and Global Assistant Controller. Before joining Medtronic PLC, Mr.

   Read the 8-K filing
9. Mar 26, 2024

   On March 26, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”) announced that Michael A. Mussallem informed the Board of Directors (the “Board”) of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company’s annual meeting of stockholders on May 7, 2024 (the “2024 Annual Meeting”). Therefore, Mr. Mussallem will not stand for election to the Board at the 2024 Annual Meeting. The Company expects to appoint Nicholas J. Valeriani, an independent director, to succeed Mr. Mussallem as Chairman of the Board. Additionally, Martha H. Marsh has reached the retirement age set forth in the Company’s Corporate Governance Guidelines and will therefore not be nominated to stand for election to the Board at the 2024 Annual Meeting. 2

   Read the 8-K filing
10. May 15, 2023

    On May 11, 2023, the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), approved an increase in Bernard J. Zovighian’s base salary level to $1,050,000 annually and increased his incentive pay objective under the Company’s annual cash incentive plan to $1,470,000 in connection with Mr. Zovighian’s previously disclosed appointment as Chief Executive Officer of the Company, in each case effective May 11, 2023.

    Read the 8-K filing
11. Dec 8, 2022

    Chief Executive Officer Retirement and Succession On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023 (the “2023 Annual Meeting”). At the 2023 Annual Meeting, Mr. Mussallem will stand for election as non-executive Chairman of the Board. At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business. On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023. Mr.

    Read the 8-K filing
12. May 5, 2021

    Retirement of Dr. William J. Link from the Board of Directors In connection with the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), Dr. William J. Link retired from the Board of Directors of the Company immediately prior to the Annual Meeting. Mr. Nicholas J. Valeriani has been appointed to succeed Dr. Link as the Chairperson of the Company’s Compensation and Governance Committee. Approval of the Amendment and Restatement of the U.S. ESPP and the International ESPP At the Annual Meeting, the Company’s stockholders approved (i) the amendment and restatement of the Company’s 2001 Employee Stock Purchase Plan for United States Employees (the “U.S. ESPP”) to increase the total number of shares of common stock available for issuance under the U.S.

    Read the 8-K filing
13. Jul 15, 2020

    On July 15, 2020, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Paul A. LaViolette was appointed to the Company’s Board of Directors, effective July 13, 2020. The Board also appointed Mr. LaViolette to serve as a member of the Compensation and Governance Committee of the Board of Directors. There is no arrangement or understanding between Mr. LaViolette and any other persons pursuant to which he was selected as a director. Mr. LaViolette has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr.

    Read the 8-K filing
14. May 12, 2017

    At the 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”) of Edwards Lifesciences Corporation (“Edwards”), stockholders of Edwards approved the amendment and restatement of Edwards’ Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”) by the affirmative vote of a majority of the shares of common stock represented at the 2017 Annual Meeting, in person or by proxy, and entitled to vote. The amendments approved by stockholders included an increase in the total number of shares of Edwards common stock available for issuance under the Long-Term Stock Program by 1,400,000 shares to a new total share limit of 109,200,000 shares.

    Read the 8-K filing
15. Jul 5, 2016

    On July 5, 2016, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Leslie S. Heisz was appointed to the Company’s Board of Directors, effective July 5, 2016. The Board also appointed Ms. Heisz to serve as a member of the Audit Committee of the Board of Directors. There is no arrangement or understanding between Ms. Heisz and any other persons pursuant to which she was selected as a director. Ms. Heisz has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Ms. Heisz will receive the same compensation and agreements as the Company’s other nonemployee directors as described in the Company’s 2016 Proxy Statement. A copy of the press release announcing her appointment is filed as Exhibit 99.1.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.